Dianthus Therapeutics, Inc.

DNTH

$107.64

-0.19%

2026-09-04 12:45:47 EDT-$0.21

Healthcare

Biotechnology

NASDAQ

Active Trading

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage ...

Price Action of DNTH

$107.64

-0.19%-$0.21

High—

Low—

52W High-8.7%

Rel. vol—

Interval

Range6.5h

Volume—SMA5SMA10

—

Key Metrics of DNTH

Snapshot

Latest / TTM · 6 periods

Market Cap

$6.02B

ROCE

-18.5%

EV / EBITDA

-201.27x

+17.1% YoY

FCF Yield

-2.6%

+5.7% YoY

Cash Conversion Cycle

-30668.5d

Current Ratio

26.10

Quick take

Financial Highlights of DNTH

Profitability trend

Latest / TTM · 6 periods

Gross Margin

96.0%

Net Margin

-1570.9%

P/E Ratio

-831.85x

n/a

Debt / Equity

0.00

n/a

Current Ratio

26.10

Dividend Yield

0.0%

Understanding

Calendar of DNTH

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.99 · Revenue $400833.00 · 6 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-1.08 · Revenue $394250.00 · 6 analysts

Financial Statements of DNTH

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of DNTH

Acquisitions (A)

Since Aug 19, 2026

Disposals (D)

Since Aug 19, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Leadership Team of DNTH

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Marino Garcia	President, Chief Executive Officer & Director	USD 1,163,750	Male	1966	Active
Simrat Randhawa	Executive Vice President and Head of R&D

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after Sanofi's setback.

Historical Employee Count of DNTH

Current

Change

+17.95%

Minimum

Maximum

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-4.20 vs -3.68	-14.2%	-0.90 vs -0.99	+8.8%
Revenue Surprise	$2.0M vs $2.2M	-7.3%	$761000 vs $400833	+89.9%

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	92	10-K	Mar 9, 2026	View
Dec 31, 2024	78	10-K	Mar 11, 2025	View
Dec 31, 2023	53	10-K	Mar 21, 2024	View

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Stock Option (Right to Buy)	D	9,375	$22.07
Sep 1, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Stock Option (Right to Buy)	D	7,500	$17.88
Sep 1, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Stock Option (Right to Buy)	D	6,249	$21.77
Sep 1, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Common Stock	A	9,375	$22.07
Sep 1, 2026	Randhawa Simrat	officer: EVP, Head of R&D	Common Stock	D	2,600	$105.19

Dianthus Therapeutics, Inc.

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Related stocksBiotechnology

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case

Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Recent Filings